The present study confirms the findings of recently published trials, in both Type 1 diabetes 17 and Type 2 diabetes basal–bolus therapy 16, which demonstrated an improvement in health-related quality of life with insulin degludec vs. insulin glargine. This evidence concerns the gene INS and type 2 diabetes mellitus.